Aprogen Medicines Inc.

Equities

A007460

KR7007460009

Industrial Machinery & Equipment

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
1,194 ^KRW	+2.49%		+0.59%	+24.38%

May. 14	Aprogen Medicines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 19	Aprogen Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aprogen Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 18, 2024 at 11:44 pm EDT

Aprogen Medicines Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 1,405.47 million compared to KRW 1,199.02 million a year ago. Net loss was KRW 55,619.38 million compared to KRW 98,656.71 million a year ago.

Basic loss per share from continuing operations was KRW 236 compared to KRW 490 a year ago. Diluted loss per share from continuing operations was KRW 236 compared to KRW 497 a year ago. Basic loss per share was KRW 236 compared to KRW 490 a year ago.

Latest news about Aprogen Medicines Inc.

Aprogen Medicines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Aprogen Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Aprogen Healthcare & Games Inc. announced that it expects to receive KRW 35.00000038 billion in funding from Aprogen Medicines Inc., G-Baise Inc.	Dec. 10	CI
Aprogen Medicines Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Aprogen Medicines Inc. announced that it has received KRW 5.5 billion in funding	23-10-22	CI
Aprogen Medicines Inc. announced that it expects to receive KRW 5.5 billion in funding	23-10-12	CI
Aprogen Medicines Inc. announced that it has received KRW 70 billion in funding	23-09-13	CI
Aprogen Medicines Inc. announced that it expects to receive KRW 70 billion in funding	23-09-07	CI
Aprogen Medicines Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Aprogen Medicines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Aprogen Biologics Inc. announced that it has received KRW 40.0000005 billion in funding from Aprogen Medicines Inc.	23-04-11	CI
Aprogen Medicines Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 50 billion in funding from Aprogen Medicines Inc.	22-10-03	CI
Aprogen Medicines Inc. completed the acquisition of remaining unknown stake in Aprogen, Inc.	22-07-17	CI
Aprogen Medicines Inc. signed a merger contract to acquire remaining unknown stake in Aprogen, Inc.	21-11-17	CI
Aprogen Medicines Inc. announced that it expects to receive KRW 105 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd., Aprogen pharmaceuticals,Inc., Aprogen Healthcare & Games Inc.	21-09-15	CI
Aprogen KIC Inc. announced that it has received KRW 20 billion in funding from Korea Bond Investment Advisory Co., Ltd.	21-01-20	CI
Aprogen KIC Inc. cancelled the acquisition of additional 5.6% stake in Aprogen pharmaceuticals,Inc..	21-01-13	CI
Aprogen KIC Inc. announced that it expects to receive KRW 20 billion in funding from Korea Bond Investment Advisory Co., Ltd.	21-01-06	CI
Aprogen KIC Inc. announced that it has received KRW 50 billion in funding from Wooridul Huebrain Ltd. and another investor	20-10-12	CI
Aprogen KIC Inc. announced that it expects to receive KRW 50 billion in funding from Wooridul Huebrain Ltd. and another investor	20-10-11	CI
Aprogen KIC Inc. cancelled the acquisition of remaining stake minority in Aprogen, Inc.	20-09-07	CI
Aprogen KIC Inc. cancelled the acquisition of Aprogen Healthcare & Games Inc..	20-09-07	CI
Aprogen KIC Inc. agreed to acquire Aprogen Healthcare & Games Inc. for approximately KRW 140 billion.	20-04-23	CI
Aprogen KIC Inc. signed a merger agreement to acquire remaining stake minority in Aprogen, Inc.	20-04-23	CI

Chart Aprogen Medicines Inc.

Duration

Period

More charts

Company Profile

Aprogen Inc, formerly Aprogen Medicines Inc, is a Korea-based company mainly engaged in the business of hardfacing. The Company operates its business through six segments. The Hardfacing segment is engaged in the provision of hardfacing for maintenance of steel mills, thermal power plants and cement plants. The Steel Sale segment is engaged in the sale of steel products, aluminum ingots and others. The Insulation segment is engaged in the nuclear thermal insulation and insulation construction. The Pharmaceutical segment is engaged in the manufacture and sale of pharmaceuticals. The Game segment is engaged in the mobile game publishing business. The Other segment is engaged in the sale of scrap metal.

Sector

Industrial Machinery & Equipment

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Welding & Soldering Equipment

	1st Jan change	Capi.
APROGEN MEDICINES INC.	+24.38%	220M
ESAB CORPORATION	+8.82%	5.7B
HAN'S LASER TECHNOLOGY INDUSTRY GROUP CO., LTD.	-3.72%	2.89B
WUXI AUTOWELL TECHNOLOGY CO.,LTD.	-16.34%	2.34B
WUHAN RAYCUS FIBER LASER TECHNOLOGIES CO.,LTD.	-21.76%	1.44B
ESAB INDIA LIMITED	-4.11%	1.05B
SBT ULTRASONIC TECHNOLOGY CO.,LTD.	-42.92%	746M
SHANGHAI HUGONG ELECTRIC GROUP CO.,LTD.	-0.20%	647M
SHENZHEN UNITED WINNERS LASER CO., LTD.	-34.52%	628M
SHENZHEN JASIC TECHNOLOGY CO.,LTD.	-1.42%	503M

Welding & Soldering Equipment